Key facts
- This page summarizes Robert Nelsen's Form 4 filing for Vir Biotechnology, Inc. (VIR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2024, 12:14.
Robert Nelsen - 30 May 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)
- Reporting relationship
- Director
- Issuer ticker
- VIR
- Reported as of
- 30 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2024, 12:14:50 UTC
- Prior SEC filing
- 20 Feb 2024
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vanina de Verneuil, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Nelsen filed Form 4 for Vir Biotechnology, Inc. (VIR) on 03 Jun 2024.
Change
- Previous filing in this sequence was filed on 20 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,000
- Change %
- +1.4%
- Price
- $0.000000
- Shares after
- 584,148
- Date
- 30 May 2024
- Ownership
- Direct
VIR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,626,008
- Date
- 30 May 2024
- Ownership
- See footnote
- Footnotes
- F1
VIR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,290,655
- Date
- 30 May 2024
- Ownership
- See footnote
- Footnotes
- F2
VIR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,893
- Date
- 30 May 2024
- Ownership
- See footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +16,000
- Change %
- Price
- $0.000000
- Shares after
- 16,000
- Date
- 30 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,000
- Exercise price
- $10.39
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.
Footnote F2
The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.
Footnote F3
Shares held by a trust for the benefit of family members of the Reporting Person.